Previous 10 | Next 10 |
Today, we put developmental biotech company Caribou Biosciences in the spotlight for the first time. This nascent gene editing concern has fallen deep in 'Busted IPO' as any enthusiasm on the biotech sector has faded substantially in recent quarters. The stock now sells for near t...
BERKELEY, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the European Hematology Association (EHA) has accepted an abstract with initial clinical data from Ca...
-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked to blunt both T- and NK-mediated immune cell rejection, enabling more durable antitumor activity -- -- Data support an expected Investigational New Drug (IND) application submission in 2022 for CB-0...
Philippe Laffont’s 13F portfolio value decreased from $24.58B to $22.55B this quarter. They increased Tesla and Microsoft while reducing Moderna, Snowflake, DoorDash, Marqeta, and Twilio. They also added Pfizer, Visa, and Applied Materials while dropping UiPath. For f...
Stanley Druckenmiller’s 13F portfolio value decreased from $3.08B to $2.76B this quarter. Duquesne increased Coupang, Carvana, Kbr, Flex, Procept Bio, and Smartsheet while decreasing Alphabet, Amazon.com, Palo Alto Networks, Starbucks, and Expedia Group. They also dropped Meta ...
CRSP needs to make tough decisions regarding the loss of critical CRISPR patents in the US. CRSP differentiates itself by creating allogeneic CAR-T therapy allowing mass production, off-shelf availability, and potentially low production cost. The company is the wealthiest CRISPR b...
Caribou Bioscience press release (NASDAQ:CRBU): Q4 GAAP EPS of -$0.31 beats by $0.05. Revenue of $2.56M (+161.2% Y/Y) misses by $0.87M. Shares +2.08% AH. For further details see: Caribou Bioscience GAAP EPS of -$0.31 beats by $0.05, revenue of $2.56M misses by $0.87M
-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate for patients with r/r B-NHL -- -- 2022 submission of IND application planned for CB-011, an allogeneic cell therapy candidate fo...
Editas has two CRISPR genome editing techniques which are CRISPR/Cas9 and CRISPR/Cas12a. EDIT-101 is being developed to treat patients with Leber congenital amaurosis type 10; Results from phase 1/2 BRILLIANCE study expected in 2nd half of 2022. EDIT-301 is being developed to trea...
BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical data from CB-011, its allogeneic anti-BCMA CAR-T cell therapy for the treatment of re...
News, Short Squeeze, Breakout and More Instantly...
Caribou Biosciences Inc. Company Name:
CRBU Stock Symbol:
NASDAQ Market:
Caribou Biosciences Inc. Website:
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today a...
2024-06-04 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for CRBU on June 4, 2024 06:46AM ET. The previous analyst recommendation was Buy. CRBU was trading at $2.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 22.3% to $0.12231 on volume of 147,748,197 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 11.8% to $0.6524 on volume of 95,235,738 shares AMC Entertainment Holdings Inc. Class A (AM...